The concept behind TRANS-INT is the rational design of oral nanomedicines based on safety, mechanistic, bioengineering and pharmaceutical technology criteria.
The consortium is composed of 16 partners from industry and academia with complementary leading expertise in chemistry, chemical engineering, pharmaceutical technology, molecular physiology, biopharmaceutics, toxicology and drug development.
FP7-NMP-2011-LARGE-5 „New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier”
The idea of TheraGlio is to develop a multimodal imaging system for Theranostics (therapy+diagnosis) of patients bearing malignant glioma, the most common primary brain tumour.
This technology will avail of new generation Microbubbles that can simultaneously act as drug delivery system and contrast agent for Magnetic Resonance Imaging, intra-operative Contrast-Enhanced Ultrasound and intra-operative fluorescence microscopic. This novel imaging system will provide multimodal image guidance during tumour resection with the final goal of prolonging patients’ survival, as a result of a safer and larger tumour resection and tailored delivery of specific chemotherapeutic molecules.
FP7-HEALTH-2013-INNOVATION-1 „Microbubble driven multimodal imaging and theranostics for gliomas”
Hungarian-Israeli Bilateral Scientific Collaboration Grant
This collaboration was started with the following aims
- Optimization of Doxebo dosage and method of administration in the porcine in vivo model
- Development of anti-PEG and anti-Doxil IgG and IgM detection methods in order to elucidate the mechanism of the immune reaction
- Development of assessment methods for plasma thromboxane and leucotrienes in domestic pig and rat
TÉT_13_IL-2-2014-0001 “Pharmacological reduction of the risk of serious adverse immune effects of liposomal medicines”